List of Orbactiv drug patents

Orbactiv is owned by Melinta Therap.

Orbactiv contains Oritavancin Diphosphate.

Orbactiv has a total of 3 drug patents out of which 0 drug patents have expired.

Orbactiv was authorised for market use on 06 August, 2014.

Orbactiv is available in powder;intravenous dosage forms.

Orbactiv can be used as treatment of bacterial skin and skin structure infections using a single dose, treatment of bacterial skin and skin structure infections.

Drug patent challenges can be filed against Orbactiv from August, 2023.

The generics of Orbactiv are possible to be released after 16 July, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(7 years from now)

US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections using a single dose; Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in